Mrugacz M, Bakunowicz-Łazarczyk A. Influence of vigabatrin on visual field
and electrophysiological tests in patients
with epilepsy. Klinika Oczna / Acta Ophthalmologica Polonica. 2003;105(5):326-329.
APA
Mrugacz, M., & Bakunowicz-Łazarczyk, A. (2003). Influence of vigabatrin on visual field
and electrophysiological tests in patients
with epilepsy. Klinika Oczna / Acta Ophthalmologica Polonica, 105(5), 326-329.
Chicago
Mrugacz, Małgorzata, and Alina Bakunowicz-Łazarczyk. 2003. "Influence of vigabatrin on visual field
and electrophysiological tests in patients
with epilepsy". Klinika Oczna / Acta Ophthalmologica Polonica 105 (5): 326-329.
Harvard
Mrugacz, M., and Bakunowicz-Łazarczyk, A. (2003). Influence of vigabatrin on visual field
and electrophysiological tests in patients
with epilepsy. Klinika Oczna / Acta Ophthalmologica Polonica, 105(5), pp.326-329.
MLA
Mrugacz, Małgorzata et al. "Influence of vigabatrin on visual field
and electrophysiological tests in patients
with epilepsy." Klinika Oczna / Acta Ophthalmologica Polonica, vol. 105, no. 5, 2003, pp. 326-329.
Vancouver
Mrugacz M, Bakunowicz-Łazarczyk A. Influence of vigabatrin on visual field
and electrophysiological tests in patients
with epilepsy. Klinika Oczna / Acta Ophthalmologica Polonica. 2003;105(5):326-329.
Vigabatrin (VGB) is a new antiepileptic drug, that acts by the irreversible inhibition of gamma-aminobutyric acid (GABA) aminotransferase. Chronic antiepileptic therapy with VGB is associated with visual field defects and electrophysiological changes.
